Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-61393215 adjunctive treatment for major depressive disorder with anxious distress
2019-001683-29Phase 2Unknown
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing JNJ-61393215 adjunctive treatment with Placebo adjunctive treatment (2 arms). Primary endpoint: Change from baseline to Week 6 in HDRS17 total score. Status: unknown.
02
Drugs
rocavorexant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2019-001683-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001683-29.